Genome-wide functional genomic and transcriptomic analyses for genes regulating sensitivity to vorinostat

Scientific Data

Volumn 1, Issue , 2014, Pages

  Falkenberg, Katrina J ^a   Gould, Cathryn M ^a   Johnstone, Ricky W ^a,b   Simpson, Kaylene J ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; SMALL INTERFERING RNA; VORINOSTAT;

CELL DEATH; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GENOMICS; HUMAN; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; RNA, SMALL INTERFERING;

EID: 84959396270     PISSN: None     EISSN: 20524463     Source Type: Journal    
DOI: 10.1038/sdata.2014.17     Document Type: Article

References (28)

1. Duvic, M. et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109, 31-39 (2007).
2. Olsen, E. A. et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25, 3109-3115 (2007).
3. Fantin, V. R. et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 68, 3785-3794 (2008).
4. Lindemann, R. K. et al. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc. Natl Acad. Sci. USA 104, 8071-8076 (2007).
5. Fotheringham, S. et al. Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitorinduced apoptosis. Cancer Cell 15, 57-66 (2009).
6. Khan, O. et al. HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy. Proc. Natl Acad. Sci. USA 107, 6532-6537 (2010).
7. Nijwening, J. H., Beijersbergen, R. L. Using large-scale RNAi screens to identify novel drug targets for cancer. IDrugs 13, 772-777 (2010).
8. Berns, K. et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 428, 431-437 (2004).
9. Mullenders, J. et al. Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. Clin. Cancer Res. 15, 5811-5819 (2009).
10. Tandle, A. T. et al. Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation. Eur. J. Cancer 49, 3020-3028 (2013).
11. Singel, S. M. et al. A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. Clin. Cancer Res. 19, 2061-2070 (2013).
12. Petrocca, F. et al. A Genome-wide siRNA Screen Identifies Proteasome Addiction as a Vulnerability of Basal-like Triple-Negative Breast Cancer Cells. Cancer Cell 24, 182-196 (2013).
13. Fredebohm, J., Wolf, J., Hoheisel, J. D., Boettcher, M. Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine. J. Cell Sci. 126, 3380-3389 (2013).
14. Xie, L. et al. A synthetic interaction screen identifies factors selectively required for proliferation and TERT transcription in p53-deficient human cancer cells. PLoS Genet. 8, e1003151 (2012).
15. MacKeigan, J. P., Murphy, L. O., Blenis, J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat. Cell Bio. 7, 591-600 (2005).
16. Falkenberg, K., Saunders, D., Simpson, K. A High-throughput, multiplex cell death assay using an RNAi screening approach. Cold Spring Harb. Protoc. 2014, doi:10.1101/pdb.prot080267 (2014).
17. Birmingham, A. et al. Statistical methods for analysis of high-throughput RNA interference screens. Nat. Methods 6, 569-575 (2009).
18. Simpson, K. J. et al. Identification of genes that regulate epithelial cell migration using an siRNA screening approach. Nat. Cell Bio. 10, 1027-1038 (2008).
19. Chia, N. Y. et al. A genome-wide RNAi screen reveals determinants of human embryonic stem cell identity. Nature 468, 316-320 (2010).
20. Smith, J. A. et al. Genome-wide siRNA screen identifies SMCX, EP400, Brd4 as E2-dependent regulators of human papillomavirus oncogene expression. Proc. Natl Acad. Sci. USA 107, 3752-3757 (2010).
21. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 7, 562-578 (2012).
22. 22.,ers, S., Pyl, P., Huber, W. HTSeq-A Python framework to work with high-throughput sequencing data. Preprint at http://dx.doi.org/10.1101/002824 (2014).
23. Robinson, M. D., McCarthy, D. J., Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140 (2010).
24. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Molec. Biol. 3, Article3 (2004).
25. Law, C. W., Chen, Y., Shi, W., Smyth, G. K. Voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
26. Brass, A. L. et al. Identification of host proteins required for HIV infection through a functional genomic screen. Science 319, 921-926 (2008).
27. Adamson, B., Smogorzewska, A., Sigoillot, F. D., King, R. W., Elledge, S. J. A genome-wide homologous recombination screen identifies the RNA-binding protein RBMX as a component of the DNA-damage response. Nat. Cell Bio. 14, 318-328 (2012).
28. D'Haeseleer, P. How does gene expression clustering work? Nature Biotechnol. 23, 1499-1501 (2005).